Matinas BioPharma | Investor Presentation Deck | 28 slides

Matinas BioPharma · 2023-08
arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

28
every slide · same image gating as the playbook
01
Slide 1
front_matter
02
The slide uses a three-column layout to contrast the lead asset with the two core technology platforms.summarize
03
The chart uses a Gantt-style visualization to show progress across discovery, preclinical, and clinical phases.plan_implementation
04
transition
05
QIDP stands for Qualified Infectious Disease Product.establish_context
Open slide detailBeat · ProblemLoop · Cost Of Inaction
06
Uses a 'Before-After-Bridge' style logic to frame the solution.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
07
Uses a process/timeline diagram to show life cycle management.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
08
The slide highlights business development traction through licensing agreements.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
09
show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
10
The chart displays survival percentages with corresponding n/N values below each bar group.analyze_data
11
The slide uses a timeline-like visualization for each patient to show the rapid decline of fungal load over a short period (12-14 days).show_traction
12
The slide uses a timeline-based process diagram to illustrate the clinical trial protocol.plan_implementation
13
IFIs stands for Invasive Fungal Infections.present_solution
14
Case study table showing patient demographics, medical history, and treatment outcomes.illustrate_case
15
analyze_data
16
The slide serves as a transition to the technology/pipeline section of the deck.transition
17
compare_peers
18
Includes a scientific diagram of the LNC structure and a list of key performance attributes.present_solution
19
The slide uses a process diagram to show the self-assembly of lipoplexes into PS-NPs.present_solution
20
Technical slide detailing biological mechanism of drug delivery platform.present_solution
21
Uses a process-flow diagram to represent maturity levels (Proven, Under Evaluation, Future).plan_implementation
22
The slide compares Matinas' PS-NP technology stability (17 weeks) against Moderna (30 days) and Pfizer/BioNTech (10 weeks) at refrigerated temperatures.show_traction
23
The slide shows quantitative radiance data (p/s/cm²/sr) comparing control groups to PS-NP LUC mRNA groups at various time points.show_traction
24
The slide highlights a partnership with 'Resilience' to scale manufacturing for Matinas Biopharma's therapeutic platforms.present_solution
25
The slide uses a grid-based timeline format to track specific technical achievements and partnership milestones.plan_implementation
26
The slide uses a three-column icon-based layout to summarize key IP milestones.present_solution
27
other
Open slide detailBeat · Team
28
The slide uses a split-layout: left side for financial summary, right side for milestones and thesis components.summarize